Back

NexaSweet Attenuates DSS-Induced Colitis and Preserves Colon Architecture in BALB/c Mice

Saxena, U.; K, S.; Kadiyala, G.; Gorantla, M.

2026-01-15 pharmacology and toxicology
10.64898/2026.01.15.699670 bioRxiv
Show abstract

We evaluated NexaSweet(R), a nutraceutical comprising fructooligosaccharides (FOS) combined with UT18 (a composition of selected amino acids and organic acid), in a dextran sulfate sodium (DSS)-induced colitis model in male BALB/c mice. Compared with DSS controls, NexaSweet improved bodyweight preservation ([~]13.4% relative improvement), reduced Disease Activity Index (DAI) by[~] 57.9%, increased colon length by[~] 32.1%, and reduced composite colon histopathology severity by[~] 53.1%, without adverse safety signals. These data support NexaSweet as a regenerationoriented, foodgrade intervention for mucosal repair. . Based on these data and by comparing with steroid therapy reported in literature, NexaSweet could be a favorable disease modifying ( not just symptomatic relief) therapeutic for gut diseases and wellness.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.